Focused On-demand Library for Probable dimethyladenosine transferase

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UNQ2

UPID:

DIM1_HUMAN

Alternative names:

DIM1 dimethyladenosine transferase 1 homolog; DIM1 dimethyladenosine transferase 1-like; Probable 18S rRNA (adenine(1779)-N(6)/adenine(1780)-N(6))-dimethyltransferase; Probable 18S rRNA dimethylase; Probable S-adenosylmethionine-6-N',N'-adenosyl(rRNA) dimethyltransferase

Alternative UPACC:

Q9UNQ2; O76025; Q9BU77; Q9UES1

Background:

Probable dimethyladenosine transferase plays a pivotal role in ribosomal RNA processing, specifically targeting two adenosines within the 18S rRNA component of the 40S ribosomal subunit. This enzymatic activity is crucial for the structural integrity and function of ribosomes, which are essential for protein synthesis in all living cells. The protein is also a key player in the assembly of the small subunit processome, facilitating RNA folding, modifications, and cleavage.

Therapeutic significance:

Understanding the role of Probable dimethyladenosine transferase could open doors to potential therapeutic strategies. Its central function in ribosome biogenesis and RNA processing highlights its potential as a target for interventions in diseases where these processes are dysregulated.